ArticleJournal of medical biochemistry2025
Clinical and biochemical efficacy zoledronic acid and denosumab combination: focus serum inflammatory factor level (serum ifcs), bone gla protein (bgp), and bone turnover markers b-collagen degradation product (b-ctx), and procollagen type 1 n-terminal propeptide (p1np).
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aging-Driven Inter-Organ Crosstalk in Postmenopausal Osteoporosis: From Immunometabolic Drift to Multisystem Frailty.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postmenopausal osteoporosis (PMOP) is a prevalent metabolic bone disorder characterized by decreased bone mineral density (BMD) and skeletal fragility, leading to increased susceptibility to fractures. The therapeutic efficacy of zoledronic acid and denosumab, two widely used agents in the treatment of osteoporosis, was investigated in this study. The primary objective was to evaluate the clinical effects of zoledronic acid and denosumab on serum inflammatory cytokine (IFC) levels and BMD in PMOP patients. Methods: A prospective, non-blinded, randomized controlled trial was conducted at our hospital from March 2021 to March 2024. Eighty PMOP patients were recruited and randomly assigned to either a control group (CG, n=40) or a treatment group (TG, n=40). The CG received zoledronic acid plus traditional treatment, while the TG received zoledronic acid plus denosumab plus traditional treatment. Clinical symptom improvement and changes in BMD were assessed and compared between the two groups. Serum IFC levels, including bone Gla protein (BGP) and bone turnover markers b-collagen degradation product (b-CTX) and procollagen type 1 N-terminal propeptide (P1NP), were measured. Results: Compared to the CG, patients in the TG demonstrated significantly increased BMD (P<0.05) and decreased levels of serum IFCs, BGP, and bone turnover markers (P<0.05). Additionally, the incidence of adverse reactions was significantly lower (P<0.05) in the TG, and the total effective rate of clinical treatment was significantly higher (P<0.05). Conclusions: The combination of zoledronic acid and denosumab exhibited improved clinical efficacy in PMOP patients, as evidenced by enhanced BMD and reduced serum IFC levels. These findings suggest that this combined treatment regimen may promote the treatment of osteoporosis by suppressing inflammatory responses, thereby providing a novel therapeutic approach for the management of PMOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.